Paper6178564
The biology and pathogenesis of coronaviruses.
Wege H and 2 others. Curr Top Microbiol Immunol, 1982. Cited by 356 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The biology and pathogenesis of coronaviruses. Papers, record 6178564. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6178564
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Coronaviridae | Major topic |
| Animals | |
| Antigens, Viral | |
| Bronchitis | |
| Cats | |
| Cattle | |
| Cross Reactions | |
| Dog Diseases | |
| Dogs | |
| Enteritis | |
| Epitopes | |
| Hepatitis | |
| Humans | |
| Mice | |
| Nucleic Acid Hybridization | |
| Peritonitis | |
| Poultry Diseases | |
| RNA, Viral | |
| Rodent Diseases | |
| Turkeys |
Source PubMed
Cited by213
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 356 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38,247,540 | Anastrozole Protects against Human Coronavirus Infection by Ameliorating the Reactive Oxygen Species-Mediated Inflammatory Response. | Antioxidants (Basel) | 2024 | https://conductscience.org/library/papers/38247540 | PubMed |
| 37,243,102 | Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III). | Vaccines (Basel) | 2023 | https://conductscience.org/library/papers/37243102 | PubMed |
| 37,197,656 | Interferon regulatory factor 3 mediates effective antiviral responses to human coronavirus 229E and OC43 infection. | Front Immunol | 2023 | https://conductscience.org/library/papers/37197656 | PubMed |
| 37,153,539 | Critical role of TLR activation in viral replication, persistence, and pathogenicity of Theiler's virus. | Front Immunol | 2023 | https://conductscience.org/library/papers/37153539 | PubMed |
| 36,851,792 | Human Coronavirus OC43 as a Low-Risk Model to Study COVID-19. | Viruses | 2023 | https://conductscience.org/library/papers/36851792 | PubMed |
| 36,754,290 | Possible spread of SARS-CoV-2 in domestic and wild animals and body temperature role. | Virus Res | 2023 | https://conductscience.org/library/papers/36754290 | PubMed |
| 35,336,888 | Clinical and Molecular Relationships between COVID-19 and Feline Infectious Peritonitis (FIP). | Viruses | 2022 | https://conductscience.org/library/papers/35336888 | PubMed |
| 35,215,991 | Reduction of Cell Fusion by Deletion in the Hypervariable Region of the Spike Protein of Mouse Hepatitis Virus. | Viruses | 2022 | https://conductscience.org/library/papers/35215991 | PubMed |
| 34,267,652 | Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34267652 | PubMed |
| 34,188,334 | Temporal evolution, most influential studies and sleeping beauties of the coronavirus literature. | Scientometrics | 2021 | https://conductscience.org/library/papers/34188334 | PubMed |
| 34,067,536 | Excessive Innate Immunity Steers Pathogenic Adaptive Immunity in the Development of Theiler's Virus-Induced Demyelinating Disease. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34067536 | PubMed |
| 33,582,855 | Viral mouse models used to study multiple sclerosis: past and present. | Arch Virol | 2021 | https://conductscience.org/library/papers/33582855 | PubMed |
| 33,331,810 | Understanding the outcomes of COVID-19 - does the current model of an acute respiratory infection really fit? | J Gen Virol | 2021 | https://conductscience.org/library/papers/33331810 | PubMed |
| 33,316,002 | Combination of C21 and ARBs with rhACE2 as a therapeutic protocol: A new promising approach for treating ARDS in patients with coronavirus infection. | Med J Islam Repub Iran | 2020 | https://conductscience.org/library/papers/33316002 | PubMed |
| 33,282,073 | Guillain-Barré syndrome associated with COVID-19 infection. | Pan Afr Med J | 2020 | https://conductscience.org/library/papers/33282073 | PubMed |
| 32,720,031 | The kidney, COVID-19, and the chemokine network: an intriguing trio. | Int Urol Nephrol | 2021 | https://conductscience.org/library/papers/32720031 | PubMed |
| 32,580,969 | Coronavirus Disease 2019-COVID-19. | Clin Microbiol Rev | 2020 | https://conductscience.org/library/papers/32580969 | PubMed |
| 32,375,268 | Coronavirus Pandemic-Therapy and Vaccines. | Biomedicines | 2020 | https://conductscience.org/library/papers/32375268 | PubMed |
| 32,313,807 | Guillain-Barré Syndrome associated with SARS-CoV-2 infection. | IDCases | 2020 | https://conductscience.org/library/papers/32313807 | PubMed |
| 32,313,392 | Equine coronavirus: An emerging enteric virus of adult horses. | Equine Vet Educ | 2016 | https://conductscience.org/library/papers/32313392 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6178564
GET https://conductscience.org/api/papers/v1/6178564/cited_by?page=2